As the UK woke up to the Labour Party's historic landslide general election victory, ending 14 years of rule by the Conservative Party, the country's pharma and biotech associations called for the new government to prioritize the sector.
UK Life Sciences Leaders Optimistic After Labour Landslide
However, the country's pharma association says that the new government "needs to hit the ground running and rapidly set out a clear, detailed plan" for what it will do in the coming weeks and years.
More from Leadership
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.